Press Releases 2017-09-13T20:17:34+00:00

Press Releases

Cardiologists Continue to Lag Nephrologists When It Comes to the Adoption of Vifor/Relypsa’s Veltassa for Hyperkalemia, but Prescribers in Both Specialties Report Mounting Market Access Pressure

At nearly two years post launch, close to 90% of nephrologists are using Veltassa compared to 61% of cardiologists and promotion could be a major factor in the difference between the specialties according to the latest quarterly update from Spherix Global Insights Download Report Overview (Cardiology) Download Report Overview (Nephrology) EXTON, Pa., Nov. 16, 2017 /PRNewswire/ -- According to survey feedback gathered from US cardiologists (n=101) and nephrologists (n=102), the use of Veltassa (patiromer FOS) continues to expand as the product enjoys a competitor-free environment. However, uptake among nephrologists continues to outpace that of cardiologists even though the number of [...]

November 16, 2017|

Advanced Practice Providers Treat Significantly More of their Multiple Sclerosis Patients with Monoclonal Antibody Disease-Modifying Therapies Compared to Neurologists in the US

Market access restrictions for these high efficacy therapies may be hindering their ability to optimally treat their clinically complex, relapsing patients, according to a new report from Spherix Global Insights Download Report Overview EXTON, Pa., Nov. 15, 2017 /PRNewswire/ -- Advanced practice providers (APPs), including nurse practitioners and physician assistants, play an important role as providers of care for patients with multiple sclerosis (MS). In a new report by Spherix Global Insights, 53 APPs were surveyed about their use of disease modifying therapies (DMTs) and their results were compared to a parallel report of 98 US neurologists. Overall, the APPs [...]

November 15, 2017|

In the CKD-MBD Market, OPKO’s Rayaldee Continues to Struggle While Keryx’s Auryxia Gains Momentum, According to Latest Quarterly Update from Spherix Global Insights

Amgen's Parsabiv, having finally received a J-code effective January 2018, is poised for rapid uptake in the dialysis market, not only off-setting Amgen's own Sensipar but expanding the calcimimetic-treated population overall Download Report Overview EXTON, Pa., Nov. 14, 2017 /PRNewswire/ -- A survey of over 200 US nephrologists fielded in late September indicates that, while many changes are afoot in the bone and mineral metabolism space, the launch of Rayaldee appears to be at a standstill. Despite Q3 reports in OPKO's earnings call about the growth in Rayaldee prescription volume, the survey results detected no notable expansion in the user [...]

November 14, 2017|

The Renal Anemia Market is on the Cusp of Change Beginning with the FDA Approval of Keryx Biopharmaceutical’s Auryxia for the Treatment of Iron Deficiency Anemia (IDA) in Adults with Chronic Kidney Disease, Not on Dialysis (CKD-ND)

New indication should bolster sales of Auryxia according to the latest reports from Spherix Global Insights Download Report Overview EXTON, Pa., Nov. 7, 2017 /PRNewswire/ -- Earlier today Keryx announced the second approval for Auryxia (ferric citrate) to treat iron deficiency anemia in patients with chronic kidney disease. It is the first oral iron product to be developed and approved specifically for this indication. Auryxia was originally approved as a phosphate binder for patients on dialysis in September 2014. So what does this mean for Auryxia and what does it mean for the treatment patterns in renal anemia in the [...]

November 7, 2017|

Janssen’s Stelara and Novartis’ Cosentyx Take the Cake When Psoriasis Patients Switch between Biologic/Otezla Agents, According To a Recent Audit of Nearly 1,000 Recently Switched Psoriasis Patients Conducted by Spherix Global Insights

Over one in five psoriasis patients are reported to switch between biologics or Celgene’s Otezla to a different brand within a given year Download Report Overview EXTON, Pa., October 31, 2017 /PRNewswire/ — Spherix Global Insights announces the release of RealWorld Dynamix™: Biologic and Otezla Switching in Psoriasis, a project undertaken in collaboration with 201 US dermatologists who provided detailed chart reviews for nearly 1,000 psoriasis (PsO) patients recently switched from one biologic or Otezla to another brand. US dermatologists estimate that more than 20% of their biologic or Otezla treated PsO patients switch to a different brand within a [...]

October 31, 2017|

US Rheumatologists Report that Use of Biologic/JAK Monotherapy in Rheumatoid Arthritis is Greatest for Pfizer’s Xeljanz, Roche/Genentech’s Actemra, and Sanofi/Regeneron’s Recently Launched Kevzara

Use of biologic/JAK monotherapy is primarily driven by adequate patient response on monotherapy, tolerability issues with traditional DMARDs, or comorbidities preventing use, according to recent findings from Spherix Global Insights Download Report Overview EXTON, Pa., October 23, 2017 /PRNewswire/ — Despite rheumatologists (n=102) reports of increased monotherapy over the past year, most feel that methotrexate (MTX) is still the backbone of rheumatoid arthritis (RA) treatment. Additionally, study respondents are largely in agreement that RA patients who take biologics/JAKs in combination with traditional disease-modifying antirheumatic drugs (tDMARDs) have a better clinical response than those on monotherapy. With newer brands, such as [...]

October 23, 2017|